Literature DB >> 20497437

RET codon 804 mutations in multiple endocrine neoplasia 2: genotype-phenotype correlations and implications in clinical management.

S Mukherjee1, D Zakalik.   

Abstract

Multiple endocrine neoplasia type 2 (MEN 2) is a genetic syndrome caused by germline mutations in the RET proto-oncogene. These mutations cause changes in either the cysteine-rich extracellular domain or, less commonly, the non-cysteine intracellular domains of the RET protein. The genotype-phenotype correlations of classical cysteine RET mutations have been the subject of several comprehensive reviews. Less is known about the characteristics of the non-cysteine RET mutations. Studies of familial medullary thyroid cancer and MEN 2A kindreds carrying non-cysteine RET mutations have revealed a wide array of phenotypes, variable penetrance, and a diverse clinical course. The observed heterogeneity in disease expression has important diagnostic, therapeutic and prognostic implications. This review summarizes the genotypic and phenotypic characteristics of RET codon 804 mutation, a prototype for the less well-defined non-cysteine RET mutations associated with MEN 2.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20497437     DOI: 10.1111/j.1399-0004.2010.01453.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  11 in total

Review 1.  Precision medicine in pheochromocytoma and paraganglioma: current and future concepts.

Authors:  P Björklund; K Pacak; J Crona
Journal:  J Intern Med       Date:  2016-05-10       Impact factor: 8.989

Review 2.  New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification.

Authors:  Joakim Crona; David Taïeb; Karel Pacak
Journal:  Endocr Rev       Date:  2017-12-01       Impact factor: 19.871

3.  Medullary Thyroid Carcinoma Associated with Germline RETK666N Mutation.

Authors:  Jian Yu Xu; Elizabeth G Grubbs; Steven G Waguespack; Camilo Jimenez; Robert F Gagel; Julie A Sosa; Rena V Sellin; Ramona Dadu; Mimi I Hu; Chardria S Trotter; Michelle Jackson; Thereasa A Rich; Samuel M Hyde; Steven I Sherman; Gilbert J Cote
Journal:  Thyroid       Date:  2016-10-18       Impact factor: 6.568

Review 4.  Multiple endocrine neoplasias type 2B and RET proto-oncogene.

Authors:  Giuseppe Martucciello; Margherita Lerone; Lara Bricco; Gian Paolo Tonini; Laura Lombardi; Carmine G Del Rossi; Sergio Bernasconi
Journal:  Ital J Pediatr       Date:  2012-03-19       Impact factor: 2.638

5.  Utility of Population-Level DNA Sequence Data in the Diagnosis of Hereditary Endocrine Disease.

Authors:  Paul J Newey; Jonathan N Berg; Kaixin Zhou; Colin N A Palmer; Rajesh V Thakker
Journal:  J Endocr Soc       Date:  2017-11-15

6.  Identification of a secondary RET mutation in a pediatric patient with relapsed acute myeloid leukemia leads to the diagnosis and treatment of asymptomatic metastatic medullary thyroid cancer in a parent: a case for sequencing the germline.

Authors:  Danielle M Pendrick; Jennifer A Oberg; Susan J Hsiao; Wendy K Chung; Carrie Koval; Anthony Sireci; Jennifer H Kuo; Prakash Satwani; Chana L Glasser; Maria Luisa Sulis; Mahesh M Mansukhani; Julia L Glade Bender
Journal:  Cold Spring Harb Mol Case Stud       Date:  2019-04-01

7.  The optimal range of RET mutations to be tested: European comments to the guidelines of the American Thyroid Association.

Authors:  Laura Fugazzola; Simone De Leo; Michela Perrino
Journal:  Thyroid Res       Date:  2013-03-14

Review 8.  Multiple endocrine neoplasia type 2: achievements and current challenges.

Authors:  Andreas Machens; Henning Dralle
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

Review 9.  Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2.

Authors:  Simona M Wagner; ShuJun Zhu; Adrian C Nicolescu; Lois M Mulligan
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

Review 10.  A differential diagnosis of inherited endocrine tumors and their tumor counterparts.

Authors:  Sergio P A Toledo; Delmar M Lourenço; Rodrigo A Toledo
Journal:  Clinics (Sao Paulo)       Date:  2013-07       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.